Background: Acalabrutinib is a selective Bruton tyrosine kinase inhibitor approved for patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell malignancy. Treatment-related adverse events (AEs) can have a negative effect on treatment adherence. Objectives: This article aims...

Background: Informational and supportive care resources are needed for Hodgkin lymphoma (HL) survivors. Objectives: The aim of this article is to adapt and evaluate a previously developed survivorship care website for HL survivors. Methods: A mixed-methods, user-centered design, including one-time...

Background: Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sézary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. Mogamulizumab is a first-in-class monoclonal antibody that selectively binds to C-C chemokine receptor 4, which is overexpressed on the...